Cargando…

Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa

The specific immune response to the Anopheles salivary peptide could be a pertinent and complementary tool to assess the risk of malaria transmission and the effectiveness of vector control strategies. This study aimed to obtain first reliable data on the current state of the Anopheles gSG6-P1 bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheteug, Glwadys, Elanga-Ndille, Emmanuel, Donkeu, Christiane, Ekoko, Wolfgang, Oloume, Martine, Essangui, Estelle, Nwane, Philippe, NSango, Sandrine Eveline, Etang, Josiane, Wanji, Samuel, Ayong, Lawrence, Eboumbou Moukoko, Carole Else
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774847/
https://www.ncbi.nlm.nih.gov/pubmed/33382730
http://dx.doi.org/10.1371/journal.pone.0242510
_version_ 1783630348347768832
author Cheteug, Glwadys
Elanga-Ndille, Emmanuel
Donkeu, Christiane
Ekoko, Wolfgang
Oloume, Martine
Essangui, Estelle
Nwane, Philippe
NSango, Sandrine Eveline
Etang, Josiane
Wanji, Samuel
Ayong, Lawrence
Eboumbou Moukoko, Carole Else
author_facet Cheteug, Glwadys
Elanga-Ndille, Emmanuel
Donkeu, Christiane
Ekoko, Wolfgang
Oloume, Martine
Essangui, Estelle
Nwane, Philippe
NSango, Sandrine Eveline
Etang, Josiane
Wanji, Samuel
Ayong, Lawrence
Eboumbou Moukoko, Carole Else
author_sort Cheteug, Glwadys
collection PubMed
description The specific immune response to the Anopheles salivary peptide could be a pertinent and complementary tool to assess the risk of malaria transmission and the effectiveness of vector control strategies. This study aimed to obtain first reliable data on the current state of the Anopheles gSG6-P1 biomarker for assess the level of exposure to Anopheles bites in high malaria endemic areas in Cameroon. Blood smears were collected from people living in the neighborhoods of Youpwe (suburban area, continental) and Manoka (rural area, Island), both areas in the coastal region of Cameroon. Malaria infection was determined using thick blood smear microscopy, whereas the level of specific IgG response to gSG-P1 peptide was assessed by enzyme-linked immunosorbent assay from the dried blood spots. Of 266 (153 from Youpwe, 113 from Manoka) malaria endemic residents (mean age: 22.8±19.8 years, age range: 6 months–94 years, male/female sex ratio: 1/1.2, with Manoka mean age: 23.71±20.53, male/female sex ratio:1/1.13 and Youpwe mean age: 22.12±19.22, male/female sex ratio 1/0.67) randomly included in the study, Plasmodium infection prevalence was significantly higher in Manoka than in Youpwe (64.6% vs 12,4%, p = 0.0001). The anti-gSG6-P1 IgG response showed a high inter-individual heterogeneity and was significantly higher among individuals from Manoka than those from Youpwe (p = 0.023). Malaria infected individuals presented a higher anti-gSG6-P1 IgG antibody response than non-infected (p = 0.0004). No significant difference in the level of specific IgG response to gSG-P1 was observed according to long lasting insecticidal nets use. Taken together, the data revealed that human IgG antibody response to Anopheles gSG-P1 salivary peptide could be also used to assess human exposure to malaria vectors in Central African region. This finding strengthens the relevance of this candidate biomarker to be used for measuring human exposure to malaria vectors worldwide.
format Online
Article
Text
id pubmed-7774847
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77748472021-01-07 Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa Cheteug, Glwadys Elanga-Ndille, Emmanuel Donkeu, Christiane Ekoko, Wolfgang Oloume, Martine Essangui, Estelle Nwane, Philippe NSango, Sandrine Eveline Etang, Josiane Wanji, Samuel Ayong, Lawrence Eboumbou Moukoko, Carole Else PLoS One Research Article The specific immune response to the Anopheles salivary peptide could be a pertinent and complementary tool to assess the risk of malaria transmission and the effectiveness of vector control strategies. This study aimed to obtain first reliable data on the current state of the Anopheles gSG6-P1 biomarker for assess the level of exposure to Anopheles bites in high malaria endemic areas in Cameroon. Blood smears were collected from people living in the neighborhoods of Youpwe (suburban area, continental) and Manoka (rural area, Island), both areas in the coastal region of Cameroon. Malaria infection was determined using thick blood smear microscopy, whereas the level of specific IgG response to gSG-P1 peptide was assessed by enzyme-linked immunosorbent assay from the dried blood spots. Of 266 (153 from Youpwe, 113 from Manoka) malaria endemic residents (mean age: 22.8±19.8 years, age range: 6 months–94 years, male/female sex ratio: 1/1.2, with Manoka mean age: 23.71±20.53, male/female sex ratio:1/1.13 and Youpwe mean age: 22.12±19.22, male/female sex ratio 1/0.67) randomly included in the study, Plasmodium infection prevalence was significantly higher in Manoka than in Youpwe (64.6% vs 12,4%, p = 0.0001). The anti-gSG6-P1 IgG response showed a high inter-individual heterogeneity and was significantly higher among individuals from Manoka than those from Youpwe (p = 0.023). Malaria infected individuals presented a higher anti-gSG6-P1 IgG antibody response than non-infected (p = 0.0004). No significant difference in the level of specific IgG response to gSG-P1 was observed according to long lasting insecticidal nets use. Taken together, the data revealed that human IgG antibody response to Anopheles gSG-P1 salivary peptide could be also used to assess human exposure to malaria vectors in Central African region. This finding strengthens the relevance of this candidate biomarker to be used for measuring human exposure to malaria vectors worldwide. Public Library of Science 2020-12-31 /pmc/articles/PMC7774847/ /pubmed/33382730 http://dx.doi.org/10.1371/journal.pone.0242510 Text en © 2020 Cheteug et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cheteug, Glwadys
Elanga-Ndille, Emmanuel
Donkeu, Christiane
Ekoko, Wolfgang
Oloume, Martine
Essangui, Estelle
Nwane, Philippe
NSango, Sandrine Eveline
Etang, Josiane
Wanji, Samuel
Ayong, Lawrence
Eboumbou Moukoko, Carole Else
Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa
title Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa
title_full Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa
title_fullStr Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa
title_full_unstemmed Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa
title_short Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa
title_sort preliminary validation of the use of igg antibody response to anopheles gsg6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of cameroon in central africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774847/
https://www.ncbi.nlm.nih.gov/pubmed/33382730
http://dx.doi.org/10.1371/journal.pone.0242510
work_keys_str_mv AT cheteugglwadys preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT elangandilleemmanuel preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT donkeuchristiane preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT ekokowolfgang preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT oloumemartine preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT essanguiestelle preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT nwanephilippe preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT nsangosandrineeveline preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT etangjosiane preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT wanjisamuel preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT ayonglawrence preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica
AT eboumboumoukokocaroleelse preliminaryvalidationoftheuseofiggantibodyresponsetoanophelesgsg6p1salivarypeptidetoassesshumanexposuretomalariavectorbitesintwoendemicareasofcameroonincentralafrica